News
Once-Monthly MariTide Shows Promising Weight Loss in Obesity and Type 2 Diabetes: Phase 2 Trial
MariTide is designed to combine the effects of glucagon-like peptide-1 (GLP-1) receptor activation with glucose-dependent insulinotropic polypeptide (GIP) receptor antagonism. This unique mechanism targets key metabolic pathways involved in appetite regulation, insulin sensitivity, and weight management.
13h
A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials.
Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...
Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...
Amgen's experimental obesity drug MariTide showed promising weight loss results with fewer side effects, according to a ...
Zacks.com on MSN12h
Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.
Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...
While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback